Noble Financial Reaffirms Outperform Rating for Tonix Pharmaceuticals (NASDAQ:TNXP)

Noble Financial restated their outperform rating on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note released on Thursday,Benzinga reports. The firm currently has a $70.00 price objective on the stock.

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They issued a “sell” rating on the stock.

Tonix Pharmaceuticals Price Performance

TNXP stock opened at $18.19 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The company’s fifty day moving average price is $18.54 and its 200-day moving average price is $19.74. Tonix Pharmaceuticals has a one year low of $6.76 and a one year high of $1,170.24. The company has a market capitalization of $34.00 million, a PE ratio of 0.00 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing the consensus estimate of ($6.23) by ($3.54). The company had revenue of $2.58 million during the quarter, compared to analysts’ expectations of $3.20 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities analysts anticipate that Tonix Pharmaceuticals will post -1762.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Two Sigma Investments LP purchased a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at about $66,000. Point72 Asset Management L.P. purchased a new stake in Tonix Pharmaceuticals during the fourth quarter valued at approximately $526,000. Jane Street Group LLC raised its position in Tonix Pharmaceuticals by 5,932.3% during the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after purchasing an additional 1,635,119 shares during the period. Northern Trust Corp purchased a new stake in Tonix Pharmaceuticals during the 4th quarter valued at $162,000. Finally, Geode Capital Management LLC raised its holdings in Tonix Pharmaceuticals by 1,600.1% during the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock valued at $650,000 after buying an additional 1,855,907 shares during the period. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.